The LifeArc Gene Therapy Innovation Fund is a £5m annual fund to support manufacture of viral vector at the world-class network of Innovation Hubs for Gene Therapies as part of LifeArc’s Rare Disease Translational Challenge.
The fund provides grants to academic researchers working to advance new gene therapies, and who require material manufactured to GMP (or GMP-like) grade to support the programme. Successful projects will be awarded funding to enable them to access the manufacturing capabilities of the Innovation Hubs for Gene Therapies.
The Gene Therapy Innovation Fund (GTIF) aims to support the advance of promising gene therapies for people living with rare conditions. There will be no expectation of a return to LifeArc on this funding, but projects must have a credible technical and financial path to significant patient benefit if they are successful.
The fund provides grants to academic researchers working to advance new gene therapies and who require material manufactured to GMP (or GMP-like) grade in order to support the programme. Funding is awarded for academics to use the manufacturing capabilities of the Innovation Hubs for Gene Therapies, and closely associated work. This is likely to include manufacturing process development, process scale-up, development of analytical methods, production of technical batches and batches manufactured in accordance with Good Manufacturing Practice (“GMP”) guidelines, to support regulatory studies and/or clinical trials. Where projects include substantial non-clinical and/or clinical studies, it is expected that applicants will secure co-funding from a suitable scheme, such as LifeArc’s Philanthropic Fund, to cover the wider translational aspects of their project, e.g., GLP safety/toxicity and/or clinical trial costs. Where the manufacturing aspects constitute part of a larger project, funding under GTIF may be conditional upon securing suitable co-funding.
You are welcome to contact us before submitting your preliminary application to ensure your project is in scope and discuss any matters such as co-funding. Please contact the Fund managers Kieran Hudson or Joanna Davidge.
Stage 1: Preliminary application and Hub allocation
Preliminary applications can be submitted at any time and are reviewed 2-3 times per year. LifeArc will review preliminary applications to ensure they are eligible for the Fund. The project will be matched to an Innovation Hub with appropriate capabilities and capacity by the Allocation Panel.
Stage 2: Develop and submit full application
LifeArc and the allocated Innovation Hub will work with the applicants to address any identified gaps before submitting a full application. In a process that will be tailored to the needs of the respective application, we will assist you to expand and refine the proposal in preparation for your submission. Full applications are reviewed twice per year, with March and September deadlines.
Stage 3: Due diligence
Once the full proposal is submitted, LifeArc will conduct due diligence on the information provided and gain external peer review. Comments will be shared with applicants who will be able to submit responses before the proposal is assessed at panel.
Stage 4: Peer review and funding decision
The funding panel will consider the submitted application, diligence, peer review, and applicant responses and make the final decision. The panel makes these project decisions twice a year, usually in June and December.
Stage 5: Funding agreement
If the panel agrees to fund the project, LifeArc will formalise the funding agreements and project milestones. If a proposal is declined, feedback will be provided for every application.
Stage 6: Milestone reports
On award, a reporting schedule will be agreed with the awardee. LifeArc and the Hub will monitor progress and will be available for support and advice where appropriate.
Stage 7: Project end and final report
The results of the project are reviewed, and the next steps discussed with the network of Innovation Hubs for Gene Therapy and LifeArc.
The allocation committee is formed of scientific and business development representatives from across the three Hubs, along with a LifeArc representative. The allocation committee will recommend the most appropriate Hub to support the project matching the project’s manufacturing needs to their individual capabilities. You may indicate a preferred Hub if you wish, but one will be assigned to you if you do not specify a preference in the preliminary application.
All applications will be reviewed by our funding panel, consisting of external expert partners from academia, charities, and industry. Read about our funding panel members here.
The next deadlines for preliminary applications are:
You can submit a preliminary application by completing and submitting the form using the link below. We ask that you contact the fund managers Kieran Hudson and Joanna Davidge prior to completing the application form.
The next deadlines for applications are:
You should hear the result of your preliminary application within one month of the preceding deadline, often sooner.
Submission of a full application to the LifeArc Gene Therapy Innovation Fund is by invitation only, and with the support of the allocated Innovation Hub.
Full applications can be submitted at any time after allocation to a Hub. The funding panel reviews full applications and makes funding decisions twice a year, in June and December. The closing date for completed, full applications to be considered at the next panel will be in March and September each year.
The initial proposal development with LifeArc and the allocated Hub is provided free of charge. Using their expertise, the allocated Hub will assist the academic applicant to deliver on a development plan with a view to the proposed project being suitably ready to the submission of a full application.
Funding decisions are based on consideration of unmet medical need, strength of the scientific rationale and supporting data and there being a clear and feasible path to patient benefit, and suitability for charitable funding. Financial, ethical, and scientific due diligence and peer review are carried out to ensure the review panel is satisfied as to the legal and technical acceptability of the research, researchers and organisation involved in carrying out the project.
Awardees are required to provide a quarterly update report from the project commencement date, alongside agreed milestone dates.
Co-funded applications are welcome with the appropriate collaboration terms outlined. Funding support will be awarded to the academic institution.
LifeArc will not ask for any financial return or intellectual property from projects supported by this grant, allowing researchers to focus purely on delivering a result that benefits patients.
We will provide feedback with the funding decision. Any invitation to reapply will be made at the funding panel’s discretion.